SCHEMBL10048336

SCHEMBL10048336

O=C1CO[C@@H]2[C@H](O)CO[C@H]12

nearest known ligand 0.44

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196060 1.00 THRB (0.44) THRBLMNAMAPT
SCHEMBL10016808 1.00 THRB (0.44) THRBLMNAMAPT
SCHEMBL1735065 1.00 THRB (0.44) THRBLMNAMAPT
SCHEMBL15218988 1.00 THRB (0.44) THRBLMNAMAPT
Isosorbide SCHEMBL699485 0.96 THRB (0.52) THRBLMNAMAPT
SCHEMBL10552467 0.75 THRB (0.41) THRBLMNAMAPT
SCHEMBL24621340 0.74
SCHEMBL372212 0.74 THRB (0.44) THRBLMNA
SCHEMBL8293189 0.74 THRB (0.44) THRBLMNA
SCHEMBL10016807 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 EP disclosed
WO-2018112774-A1 PROCESS FOR PREPARING ISOMANNIDE, MONOKETONES AND MIXTURES THEREOF RHODIA OPERATIONS (FR) 2018-06-28 WO disclosed
WO-2016099788-A1 PREPARATION OF ISOHEXIDE TRIFLUOROACETATES ARCHER DANIELS MIDLAND COMPANY (US) 2016-06-23 WO disclosed
US-20120041216-A1 METHOD FOR PRODUCING MULTICYCLICAL RING SYSTEMS CARRYING AMINO GROUPS EVONIK DEGUSSA GMBH (DE) 2012-02-16 US disclosed
US-20110077254-A1 COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2011-03-31 US disclosed
US-20070254920-A1 Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use AERIE PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
EP-0230557-A2 2,6-Dioxabicyclo[3.3.0]octane derivatives, their preparation and use as medicament Heinrich Mack Nachf. (DE) 1987-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254920-A1 Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use HCAR1, HCAR2, PAICS THRB 1067/4885LMNA 3188/4885MAPT 3694/4885
US-20110077254-A1 COMPOUNDS CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 THRB 1107/4885LMNA 1409/4885MAPT 1751/4885
US-20120041216-A1 METHOD FOR PRODUCING MULTICYCLICAL RING SYSTEMS CARRYING AMINO GROUPS AKR7A2, AADAT, OAT THRB 3156/4885LMNA 2418/4885MAPT 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.